Paradigm is a healthcare technology company focused on improving access to clinical research for patients.

Paradigm's mission is to create equitable access to the best possible care for any patient anywhere.

Paradigm was conceived in 2022 by ARCH Venture Partners, and co-incubated by ARCH and General Catalyst. The company is headquartered in New York, with operations across the United States.

Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers.

Paradigm's seamless infrastructure breaks down barriers across the trial ecosystem, giving healthcare providers and trial sponsors an unprecedented opportunity to work together to conduct trials more effectively and bring potentially life-saving therapies to patients faster.

Paradigm has also acquired Deep Lens, a leader in technology-enabled clinical trial patient recruitment in oncology leveraging electronic medical records and genomics data.

Paradigm was launched with a $203M Series A funding on Jan 27, 2023. The round was co-led by ARCH Venture Partners and General Catalyst, with participation from F-Prime Capital, GV, LUX Capital, Mubadala Capital, and Magnetic Ventures, and strategic investors including the American Cancer Society’s BrightEdge.